Clinical Trials Logo

Dyslipidemias clinical trials

View clinical trials related to Dyslipidemias.

Filter by:

NCT ID: NCT00192621 Completed - HIV Infections Clinical Trials

Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects

Start date: November 2004
Phase: Phase 4
Study type: Interventional

This is a randomised study of the effect of treatment with Combivir (zidovudine [AZT] and lamivudine [3TC]) and Kaletra (lopinavir [LPVr]), alone and in combination, on the development of abnormalities in lipid and glucose metabolism in HIV negative healthy subjects.

NCT ID: NCT00174304 Completed - Hypertension Clinical Trials

Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.

JEWEL II
Start date: October 2004
Phase: Phase 4
Study type: Interventional

To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.

NCT ID: NCT00171327 Completed - Hypertension Clinical Trials

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

Start date: July 2004
Phase: Phase 4
Study type: Interventional

Patients with mild to moderate hypertension, dyslipidemia (imbalanced blood lipids) and decreased vascular dilatation, receiving a cholesterol lowering diet were given either valsartan or fluvastatin for 8 weeks. At week 8 all patients were administered a combination treatment with valsartan 160 mg and fluvastatin 80 mg.

NCT ID: NCT00171288 Completed - Dyslipidemia Clinical Trials

Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone

Start date: August 2003
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess the effect of the combination treatment on C-reactive protein and inflammatory markers as well as the safety and tolerability in a Spanish population

NCT ID: NCT00171262 Completed - Dyslipidemia Clinical Trials

Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers

Start date: August 2004
Phase: Phase 4
Study type: Interventional

To analyze efficacy of fluvastatin on patients with chronic renal disease by analyzing certain inflammatory markers. In addition, tolerability and safety will also be evaluated in a Spanish population.

NCT ID: NCT00171236 Completed - Mixed Dyslipidemia Clinical Trials

Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

Start date: October 2001
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the safety and efficacy of fluvastatin in children diagnosed with heterozygous familial hypercholesterolemia

NCT ID: NCT00169871 Completed - Dyslipidemia Clinical Trials

Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia

Start date: March 2005
Phase: Phase 4
Study type: Observational

The objective of this proposal is to study the applicability of the hs-CRP assay in the assessment of CV risk in daily clinical conditions where hyperlipidemic population with or without CHD are currently evaluated.

NCT ID: NCT00169559 Completed - Dyslipidaemias Clinical Trials

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Start date: November 2003
Phase: Phase 2
Study type: Interventional

An eight week comparison of the investigational drug GW590735, placebo, and the marketed drug fenofibrate intended to increase the levels of "good cholesterol" and decrease levels of "bad cholesterol" in healthy patients with low levels of good cholesterol and high levels of bad cholesterol.

NCT ID: NCT00158899 Completed - Dyslipidaemia Clinical Trials

GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol

Start date: August 2004
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to compare up to 3 doses of an investigational drug GW501516 to placebo (an inactive pill that looks like GW501516) to see if it is safe, well tolerated and effective in improving (raising) low levels of "good cholesterol", high-density lipoprotein cholesterol (HDLc), as compared to placebo.

NCT ID: NCT00150384 Completed - Hypertension Clinical Trials

Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population

CAPABLE
Start date: July 2004
Phase: Phase 4
Study type: Interventional

The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population